Current Gemcitabine News and Events

Current Gemcitabine News and Events, Gemcitabine News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 6 | 208 Results
New biomarker may predict which pancreatic cancer patients respond to CD40 immunotherapy
Inflammation in the blood could serve as a new biomarker to help identify patients with advanced pancreatic cancer who won't respond to the immune-stimulating drugs known as CD40 agonists, suggests a new study from researchers in the Abramson Cancer Center of the University of Pennsylvania published in JCI Insight. (2021-02-04)

Selected gene mRNA expression is not predictive of improved overall survival
)-- A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected stage II-III non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer. (2021-01-30)

Nanoparticle drug delivery technique shows promise for treating pancreatic cancer
Veterans Affairs researchers have designed a new way to deliver pancreatic cancer drugs that could make fighting the disease much easier. (2021-01-28)

Pre-surgery chemotherapy is possible for early stage pancreatic cancer patients
A first-of-its-kind randomized clinical trial found that patients with pancreatic cancer didn't live any longer than expected after receiving pre-operative chemotherapy from either of the two standard regimens, according to trial results published in JAMA Oncology. (2021-01-21)

Disrupting the cellular process that promotes pancreatic cancer's deadly growth
Researchers say they've identified a way to disrupt a process that promotes the growth of pancreatic cancers -- one of the most difficult and deadly cancers to treat. (2020-12-08)

Potential cancer therapy may boost immune response
A new approach to cancer therapy shows potential to transform the commonly used chemotherapy drug gemcitabine into a drug that kills cancer cells in a specialized way, activating immune cells to fight the cancer, according to a study led by Cedars-Sinai Cancer investigators. (2020-12-07)

Predicting the risk of severe side effects of cancer treatment
The risk of serious adverse effects on the blood status and bone marrow of patients during chemotherapy can be predicted by a model developed at Linköping University, Sweden. This research may make it possible to use genetic analysis to identify patients with a high probability of side effects. The study has been published in npj Systems Biology and Applications. (2020-11-12)

'Time machine' offers new pancreatic cancer drug testing approach
Drug resistance is a major reason why pancreatic cancer has a five-year survival rate of only about 10%. If scientists tested potential drugs on multiple tumor cell subtypes rather than on just one subtype, they may be able to catch resistance better, suggests a ''time machine'' developed by Purdue University engineers. (2020-10-29)

Effectiveness of gemcitabine & daily RT for bladder preservation in muscle-invasive bladder cancer
Bladder preservation with trimodality therapy can be a safe and effective alternative to cystectomy for selected patients with muscle-invasive bladder cancer. The phase II NRG Oncology NRG-RTOG 0712 trial evaluated two regimens. One was the prior RTOG standard using 5-flourouracil and cisplatin with twice daily radiation (FCT), and the other a regimen of gemcitabine and daily radiation (GD) which had demonstrated efficacy in single institution clinical trials. (2020-10-26)

Sortilin may hold the key to combat pancreatic cancer more effectively
Pancreatic cancer has an extremely poor prognosis; it is the third most common cause of cancer deaths in the United States. In a novel study published in The American Journal of Pathology, published by Elsevier, scientists report the discovery of an increased level of the neuroprotein sortilin in pancreatic cancer cells that may open up the way to developing more effective treatment. (2020-08-20)

Early clinical trial tests treatment strategy for pancreatic cancer
Pancreatic cancer carries a poor prognosis, and it often goes undetected until advanced stages. A new BJS (British Journal of Surgery) study indicates that a certain cocktail of chemotherapy drugs may be a safe and effective treatment option for patients with a metastatic form of the disease. (2020-07-08)

Drug with new approach on impeding DNA repair shows promise in first clinical trial
Berzosertib, an ATR-targeting drug, improves progression-free survival in combination with chemotherapy in patients with high-grade serous ovarian cancer. (2020-06-15)

SWOG researchers go digital at ASCO20 Virtual Scientific Program
Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31. (2020-05-18)

Despite failures, chemo still promising against dangerous childhood brain cancer, DIPG
University of Colorado Cancer Center study shows, '... medicine does reach DIPG tissue in good quantities that have the potential to be effective against the tumor,' says lead researcher. (2020-03-25)

Oncotarget: Prognostic and predictive factors in pancreatic cancer
Oncotarget Volume 11, Issue 10 reported that there are not standardized predictive biomarkers able to identify patients who benefit most from treatments. (2020-03-13)

Cheap drug may alleviate treatment-resistance in leukemia
A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML), one of the most common forms of blood cancer. This is the conclusion of a study in mice and human blood cells performed at Karolinska Institutet and SciLifeLab and published in the medical journal EMBO Molecular Medicine. The researchers will now launch a clinical study to test the new combination treatment in patients. (2020-01-17)

Study finds new way to make chemotherapy more effective against pancreatic cancer
Pancreatic adenocarcinoma (PDAC) is a lethal malignancy that most often is resistant to chemotherapy. Researchers have been searching for ways to increase the sensitivity of the tumors to cancer-fighting drugs. A Mayo Clinic-led study published today opens a promising new front in that battle. (2019-09-18)

New drug shows encouraging survival in pancreatic cancer
A phase 1 clinical trial testing a new drug in pancreatic cancer had promising initial results, report researchers from the University of Michigan Rogel Cancer Center. The trial looked at AZD1775, an inhibitor designed to block an enzyme called Wee1, which plays a role in DNA damage repair. (2019-08-14)

Pancreatic cancer: Less toxic, more enduring drug may improve therapy
A new drug that penetrates the protective barrier around pancreatic cancers and accumulates in malignant cells may improve current chemotherapy, a study in mice suggests. (2019-08-08)

'Promising' antibody therapy extends survival in mice with pancreatic cancer
Scientists have found a way to target and knock out a single protein that they have discovered is widely involved in pancreatic cancer cell growth, survival and invasion. (2019-07-31)

Targeting old bottleneck reveals new anticancer drug strategy
The enzyme ribonucleotide reductase is a bottleneck for cancer cell growth. Scientists at Winship Cancer Institute of Emory University have identified a way of targeting ribonucleotide reductase that may avoid the toxicity of previous approaches, informing focused drug discovery efforts. (2019-07-22)

EGLN inhibitor protects normal tissue and enables RT in mouse model of pancreatic cancer
Administration of the EGLN inhibitor FG-4592 prior to ablative radiotherapy provided protection against fatal gastrointestinal bleeding and improved survival in a mouse model of unresectable pancreatic cancer. (2019-04-30)

Tumor-associated immune cells hinder frontline chemotherapy drug in pancreatic cancer
A frontline chemotherapy drug given to patients with pancreatic cancer is made less effective because similar compounds released by tumor-associated immune cells block the drug's action, research led by the University of Michigan Rogel Cancer Center found. (2019-03-26)

Study evaluates efficacy and safety of pancreatic cancer treatment
In a new study published in the Journal of Clinical Oncology, Manuel Hidalgo, MD, PhD, and colleagues conducted a phase I/II trial designed to evaluate the efficacy and safety of nab-paclitaxel given in combination with gemcitabine in patients with pancreatic cancer and reduced health status. (2018-12-12)

Erlotinib improves progression-free survival in early mutated non-small cell lung cancer
Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer (NSCLC), shows a randomised study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich. (2018-10-21)

Drug for pancreatic cancer developed by college of pharmacy researchers
University of Houston researchers have developed a new medicine that can inhibit two of the major pathways of pancreatic cancer. The new synthetic compound is based on a type of sea sponge. (2018-09-11)

Moffitt researchers compare chemotherapy regimens for best outcomes in invasive bladder cancer
Patients with muscle-invasive bladder cancer have been shown to benefit from chemotherapy prior to surgical removal of the bladder. But which type of chemotherapy leads to the best outcomes in terms of complete response rates or cancer control? Moffitt Cancer Center researchers examined data from more than 800 surgical patients with advanced bladder cancer. The results, published online by JAMA Oncology, show higher likelihoods of complete response or down-staging associated with a chemotherapeutic combination called ddMVAC. (2018-08-31)

Cannabinoid improves survival rates of mice with pancreatic cancer
Mice with pancreatic cancer that were treated with a naturally occurring constituent of medicinal cannabis alongside chemotherapy, survived almost three times longer than those treated with chemotherapy alone, a new study reports. (2018-07-30)

Simple post-surgery step reduces bladder cancer recurrence
In the latest issue of JAMA, SWOG researchers show that flushing the bladder with a common chemotherapy drug immediately after surgery significantly reduces the chances of bladder cancer returning. (2018-05-08)

The 'immuno revolution': Turning up the heat on resistant tumors
A promising class of drugs known as CD40 monoclonal antibodies could be the spark needed to light the fire in the immune system of patients who don't respond to the newer cancer immunotherapies. Robert H. Vonderheide, M.D., D.Phil., director of the Abramson Cancer Center at the University of Pennsylvania and an internationally renowned cancer immunotherapy expert, makes the case for the drugs in a new perspective piece published this week in Cancer Cell. (2018-04-09)

New therapeutic gel shows promise against cancerous tumors
Scientists at the UNC School of Medicine and NC State have created an injectable gel-like scaffold that can hold combination chemo-immunotherapeutic drugs and deliver them locally to tumors in a sequential manner. The results in animal models so far suggest this approach could one day ramp up therapeutic benefits for patients bearing tumors or after removal of the primary tumors. (2018-02-21)

IDIBELL researchers successfully test a new combination therapy in sarcomas
Researchers of the Sarcoma group of the Oncobell program -- Bellvitge Biomedical Research Institute (IDIBELL) have successfully tested a new combined therapy for the treatment of this rare, aggressive tumor type, which affects children and adults. (2018-01-16)

Certain factors may predict lung cancer patients' response to chemotherapy
In a retrospective analysis of 73 lung squamous cell carcinoma patients treated with the chemotherapy regimen of gemcitabine plus cisplatin, higher body mass index and younger age were linked with longer progression-free survival, the length of time that a patient lives with cancer but it does not get worse. Patients with better response to treatment and higher body mass index had longer overall survival in the Thoracic Cancer analysis. (2018-01-10)

Treatment based On BRCA1 level does not increase survival of stage II/III NSCLC N+ resected patients
Research shows that treating stage II and III non-small cell lung cancer (NSCLC) N+ resected patients with customized chemotherapy treatment based on their specific BRCA1 expression levels, as opposed to providing the standard treatment, did not increase overall survival rates among those patients who received individualized CT treatment. Dr. Bartomeu Massuti of Alicante University Hospital in Spain presented his findings today at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. (2017-10-16)

DSI professor conducts research to combat pancreatic cancer
Tal Danino, a professor at the Data Science Institute, is conducting research that could help scientists combat the most lethal of cancers: pancreatic cancer. In a recent study, working with a team of researchers, Danino demonstrated that bacteria in pancreatic tumors degrade a chemotherapy drug -- Gemcitabine -- most commonly used to treat patients who have pancreatic cancer. (2017-10-05)

How bacteria hinder chemotherapy
Scientists find bacteria in pancreatic tumors that metabolize a common drug. (2017-09-18)

Comparing cancer drug effectiveness from cells to mice to man
Dartmouth researchers who studied the cancer drug gemcitabine in cell culture, mouse models and humans have shown that the drug, at administered (tolerated) dose, arrests cell growth during cancer progression. This information can lead to better understanding how gemcitabine can be combined with other drugs at identified phases to more effectively treat cancer. (2017-09-06)

Gene-regulatory factors shown to improve pancreatic cancer response to chemotherapy
TMDU researchers revealed that, in pancreatic cancer, the microRNAs miR-509-5p and miR-1243 can promote E-cadherin expression and thereby reduce the likelihood of cells undergoing epithelial-mesenchymal transition, or indeed reverse this transition. This ability to stop cells from adopting a phenotype linked to high migration and invasiveness was also shown to synergistically increase the cancer cell-killing efficacy of gemcitabine, which is promising for developing more effective combinatorial treatments for pancreatic cancer. (2017-08-01)

Tumor-targeting drug shows potential for treating bone cancer patients
The treatment of osteosarcoma, the most common tumor of bone, is challenging. A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness. (2017-07-12)

Simple post-surgery step significantly reduces bladder cancer recurrence
It's just one step. Flushing the bladder with a common chemotherapy drug after a cancerous tumor is surgically removed reduces the chances of that cancer returning. Canadian and European clinical trials have proven this true and now a major US study has done the same. Results from the SWOG study will be presented at American Urological Association annual meeting held May 12-16 in Boston. (2017-05-15)

Page 1 of 6 | 208 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.